169 related articles for article (PubMed ID: 37648672)
1. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies.
Campbell BA; Dobos G; Haider Z; Prince HM; Bagot M; Evison F; van der Weyden C; McCormack C; Ram-Wolff C; Miladi M; Scarisbrick JJ
Blood Adv; 2023 Nov; 7(21):6639-6647. PubMed ID: 37648672
[TBL] [Abstract][Full Text] [Related]
2. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome.
Gao C; McCormack C; van der Weyden C; Goh MS; Campbell BA; Twigger R; Buelens O; Harrison SJ; Khoo C; Lade S; Prince HM
Blood; 2019 Oct; 134(16):1346-1350. PubMed ID: 31467061
[TBL] [Abstract][Full Text] [Related]
3. A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome.
Hanel W; Briski R; Ross CW; Anderson TF; Kaminski MS; Hristov AC; Wilcox RA
Am J Hematol; 2016 Dec; 91(12):E491-E495. PubMed ID: 27649045
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina.
Baquero Rey JA; Zambrano Franco EA; Andrade Miranda A; Marciano S; Mazzuoccolo LD; Enz PA
J Clin Apher; 2021 Dec; 36(6):815-822. PubMed ID: 34478581
[TBL] [Abstract][Full Text] [Related]
6. Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides/Sézary syndrome using Time to Next Treatment as a measure of clinical benefit: An EORTC CLTG study.
Mitsunaga K; Bagot M; Ram-Wolff C; Guenova E; von Gugelberg C; Hodak E; Amitay-Laish I; Papadavid E; Jonak C; Porkert S; Scarisbrick J; Applewaite R; Beylot-Barry M; Nicolay J; Quaglino P; Sanches JA; Cury-Martins J; Lora-Pablos D; Ortiz P
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38596857
[TBL] [Abstract][Full Text] [Related]
7. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.
Hughes CF; Khot A; McCormack C; Lade S; Westerman DA; Twigger R; Buelens O; Newland K; Tam C; Dickinson M; Ryan G; Ritchie D; Wood C; Prince HM
Blood; 2015 Jan; 125(1):71-81. PubMed ID: 25336628
[TBL] [Abstract][Full Text] [Related]
8. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
9. Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndrome.
Bouwhuis SA; el-Azhary RA; Gibson LE; McEvoy MT; Pittelkow MR
J Am Acad Dermatol; 2002 Jul; 47(1):63-7. PubMed ID: 12077583
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone.
Fraser-Andrews E; Seed P; Whittaker S; Russell-Jones R
Arch Dermatol; 1998 Aug; 134(8):1001-5. PubMed ID: 9722731
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome.
Booken N; Weiss C; Utikal J; Felcht M; Goerdt S; Klemke CD
J Dtsch Dermatol Ges; 2010 Jun; 8(6):428-38. PubMed ID: 20180887
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome.
Iselin C; Chang YT; Schlaepfer T; Fassnacht C; Dimitriou F; Nägeli M; Pascolo S; Hoetzenecker W; Bobrowicz M; Guenova E
Oncoimmunology; 2021 Jan; 10(1):1873530. PubMed ID: 33643690
[TBL] [Abstract][Full Text] [Related]
14. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single-centre experience.
Atzmony L; Amitay-Laish I; Gurion R; Shahal-Zimra Y; Hodak E
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2382-9. PubMed ID: 26299651
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome.
Fritz TM; Kleinhans M; Nestle FO; Burg G; Dummer R
Br J Dermatol; 1999 Jun; 140(6):1144-7. PubMed ID: 10354086
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
[TBL] [Abstract][Full Text] [Related]
19. Sézary syndrome and seronegative polyarthritis: treatment with extracorporeal photochemotherapy.
Macheiner W; Jantschitsch C; Graninger W; Pálóczy K; Bálint G; Marschalkó M; Kainberger F; Breier F; Knobler RM
J Am Acad Dermatol; 2003 Feb; 48(2):220-6. PubMed ID: 12582392
[TBL] [Abstract][Full Text] [Related]
20. African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center.
Martini DJ; Goyal S; Switchenko JM; Lechowicz MJ; Allen PB
Leuk Lymphoma; 2022 Sep; 63(9):2094-2101. PubMed ID: 35481397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
